Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 에스뻬셜리데드스 라티나스 메디까망토스 위니베르살레스 에스.아.filedCritical원본미기재
Priority to KR1019880013689ApriorityCriticalpatent/KR900005980A/en
Publication of KR900005980ApublicationCriticalpatent/KR900005980A/en
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.
Claims (9)
다음 구조식을 갖는 α-[[(2-하이드록시-1,1-디메틸-에틸)아민]메틸]벤젠 메탄올 하이드로클로라이드의 치료적 효과량을 염증이 있는 대상자에게 투여하는 것으로 구성되는 염증의 치료방법.A method of treating inflammation consisting of administering a therapeutically effective amount of α-[[(2-hydroxy-1,1-dimethyl-ethyl) amine] methyl] benzene methanol hydrochloride to the inflamed subject having the structure .제1항에 있어서, 상기 대상자에게 투여하는 방법이 경구적 주입에 의한 것인 방법.The method of claim 1, wherein the method of administering to the subject is by oral infusion.제1항에 있어서, 상기 치료적 효과량이 약 100mg/체중 kg인 방법.The method of claim 1, wherein said therapeutically effective amount is about 100 mg / kg body weight.제1항에 있어서, 상기 투여방법이 국소적 도포에 의한 것인 방법.The method of claim 1, wherein the method of administration is by topical application.제4항에 있어서, 상기 치료적 효과량이 수성 또는 알콜 용액내 6% 농도인 방법.The method of claim 4, wherein said therapeutically effective amount is a 6% concentration in aqueous or alcoholic solution.제1항에 있어서, 상기 투여방법이 질 관주법에 의한 것인 방법.The method of claim 1, wherein the administration method is by vaginal irrigation.제6항에 상기 치료적 효과량이 5%농도의 용액인 방법.The method of claim 6, wherein the therapeutically effective amount is a solution at a concentration of 5%.다음 구조식의 α-[[(2-하이드록시-1,1-디메틸-에틸)아민]메틸]벤젠 메탄올 하이드로클로라이드로 구성된 항염증제.An anti-inflammatory agent consisting of α-[[(2-hydroxy-1,1-dimethyl-ethyl) amine] methyl] benzene methanol hydrochloride of the formula:제약학적으로 허용가능한 부형제 또는 시약, 및 다음 구조식인 α-[[(2-하이드록시-1,1-디메틸-에틸)아민]메틸]벤젠 메탄올 하이드로클로라이드의 치료적 효과량으로 구성된 제약학적 조성물.A pharmaceutical composition comprising a pharmaceutically acceptable excipient or reagent and a therapeutically effective amount of the following structural formula α-[[(2-hydroxy-1,1-dimethyl-ethyl) amine] methyl] benzene methanol hydrochloride.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
Pharmaceutical composition containing L-carnitine and acyl L-carnitine for long-term treatment of non-insulin dependent diabetic patients and use thereof
Use of GM₁monosialogangliosides and their internal ester derivatives in humans to prevent the development of resistance to the analgesic effects of morphine and homologues in humans